Intratumor IL-17-positive mast cells are the major source of the IL-17 that is predictive of survival in gastric cancer patients

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Liu, Xiaosun ^a   Jin, Hailong ^a   Zhang, Geer ^a   Lin, Xianke ^a   Chen, Chao ^a   Sun, Jianyi ^a   Zhang, Yu ^a   Zhang, Qing ^a   Yu, Jiren ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17;

FEMALE; HUMAN; MALE; MAST CELL; METABOLISM; MIDDLE AGED; PATHOLOGY; STOMACH TUMOR; SURVIVAL;

FEMALE; HUMANS; INTERLEUKIN-17; MALE; MAST CELLS; MIDDLE AGED; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84908668405     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106834     Document Type: Article

References (43)

1. Tartour EFF, Joyeux I, Galinha A, Gey A (1999) Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res 59: 3698-3704.
2. Numasaki M, Watanabe M, Suzuki T, Takahashi H, Nakamura A, et al. (2005) IL-17 enhances the net angiogenic activity and in vivo growth of human nonsmall cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 175: 6177-6189.
3. de Boer OJ, van der Meer JJ, Teeling P, van der Loos CM, Idu MM, et al. (2010) Differential expression of interleukin-17 family cytokines in intact and complicated human atherosclerotic plaques. J Pathol 220: 499-508.
4. Yapici U, Kers J, Bemelman FJ, Roelofs JJ, Groothoff JW, et al. (2011) Interleukin-17 positive cells accumulate in renal allografts during acute rejection and are independent predictors of worse graft outcome. Transpl Int 24: 1008-1017.
5. He JJ, Li S, Shu HF, Yu SX, Liu SY, et al. (2013) The interleukin 17 system in cortical lesions in focal cortical dysplasias. J Neuropathol Exp Neurol 72: 152-163.
6. Zhu X, Mulcahy LA, Mohammed RA, Lee AH, Franks HA, et al. (2008) IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res 10: R95.
7. Yamada Y, Saito H, Ikeguchi M (2012) Prevalence and clinical relevance of Th17 cells in patients with gastric cancer. J Surg Res 178: 685-691.
8. Zhuang Y, Peng LS, Zhao YL, Shi Y, Mao XH, et al. (2012) CD8(+) T cells that produce interleukin-17 regulate myeloid-derived suppressor cells and are associated with survival time of patients with gastric cancer. Gastroenterology 143: 951-962 e958.
9. Le Gouvello S, Bastuji-Garin S, Aloulou N, Mansour H, Chaumette MT, et al. (2008) High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Gut 57: 772-779.
10. Wang L, Yi T, Zhang W, Pardoll DM, Yu H (2010) IL-17 enhances tumor development in carcinogen-induced skin cancer. Cancer Res 70: 10112-10120.
11. Gu FM, Gao Q, Shi GM, Zhang X, Wang J, et al. (2012) Intratumoral IL-17(+) cells and neutrophils show strong prognostic significance in intrahepatic cholangiocarcinoma. Ann Surg Oncol 19: 2506-2514.
12. Zhang JP, Yan J, Xu J, Pang XH, Chen MS, et al. (2009) Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 50: 980-989.
13. Hueber AJ, Asquith DL, Miller AM, Reilly J, Kerr S, et al. (2010) Cutting Edge: Mast Cells Express IL-17A in Rheumatoid Arthritis Synovium. The Journal of Immunology 184: 3336-3340.
14. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
15. Van De Velde AL, Anguille S, Berneman ZN (2012) Immunotherapy in leukaemia. Acta Clin Belg 67: 399-402.
16. Zheng YW, Li RM, Zhang XW, Ren XB (2013) Current adoptive immunotherapy in non-small cell lung cancer and potential influence of therapy outcome. Cancer Invest 31: 197-205.
17. Walkington LA, Lorigan P, Danson SJ (2013) Advances in the treatment of late stage melanoma. BMJ 346: f1265.
18. Balkwill F, Charles KA, Mantovani A (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7: 211-217.
19. Hanahan D,Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
20. Zhang GE, Jin HL, Lin XK, Chen C, Liu XS, et al. (2013) Anti-tumor effects of mfn2 in gastric cancer. Int J Mol Sci 14: 13005-13021.
21. Fang J, Shing Y, Wiederschain D, Yan L, Butterfield C, et al. (2000) Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci U S A 97: 3884-3889.
22. Song C, Luo L, Lei Z, Li B, Liang Z, et al. (2008) IL-17-producing alveolar macrophages mediate allergic lung inflammation related to asthma. J Immunol 181: 6117-6124.
23. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, et al. (2009) Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114: 1141-1149.
24. Korn T, Bettelli E, Oukka M, Kuchroo VK (2009) IL-17 and Th17 Cells. Annu Rev Immunol 27: 485-517.
25. Huang B, Lei Z, Zhang GM, Li D, Song C, et al. (2008) SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood 112: 1269-1279.
26. Lin AM, Rubin CJ, Khandpur R, Wang JY, Riblett M, et al. (2011) Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol 187: 490-500.
27. Noordenbos T, Yeremenko N, Gofita I, van de Sande M, Tak PP, et al. (2012) Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum 64: 99-109.
28. Wang B, Li L, Liao Y, Li J, Yu X, et al. (2013) Mast cells expressing interleukin 17 in the muscularis propria predict a favorable prognosis in esophageal squamous cell carcinoma. Cancer Immunol Immunother 62: 1575-1585.
29. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, et al. (2003) Interleukin-17 promotes angiogenesis and tumor growth. Blood 101: 2620-2627.
30. He D, Li H, Yusuf N, Elmets CA, Li J, et al. (2010) IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J Immunol 184: 2281-2288.
31. Takahashi H, Numasaki M, Lotze MT, Sasaki H (2005) Interleukin-17 enhances bFGF-, HGF- and VEGF-induced growth of vascular endothelial cells. Immunol Lett 98: 189-193.
32. Chung AS, Wu X, Zhuang G, Ngu H, Kasman I, et al. (2013) An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med 19: 1114-1123.
33. Blair RJ, Meng H, Marchese MJ, Ren S, Schwartz LB, et al. (1997) Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor. J Clin Invest 99: 2691-2700.
34. Honorati MC, Cattini L, Facchini A (2007) Possible prognostic role of IL-17R in osteosarcoma. J Cancer Res Clin Oncol 133: 1017-1021.
35. Haudenschild D, Moseley T, Rose L, Reddi AH (2002) Soluble and transmembrane isoforms of novel interleukin-17 receptor-like protein by RNA splicing and expression in prostate cancer. J Biol Chem 277: 4309-4316.
36. Murugaiyan G, Saha B (2009) Protumor vs antitumor functions of IL-17. J Immunol 183: 4169-4175.
37. Nakae S, Suto H, Berry GJ, Galli SJ (2007) Mast cell-derived TNF can promote Th17 cell-dependent neutrophil recruitment in ovalbumin-challenged OTII mice. Blood 109: 3640-3648.
38. Kono H, Fujii H, Ogiku M, Hosomura N, Amemiya H, et al. (2011) Role of IL-17A in neutrophil recruitment and hepatic injury after warm ischemiareperfusion mice. J Immunol 187: 4818-4825.
39. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, et al. (2001) Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61: 4766-4772.
40. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, et al. (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169: 2756-2761.
41. Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, et al. (2011) Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 475: 226-230.
42. Nie X, Cai G, Zhang W, Wang H, Wu B, et al. (2012) Lipopolysaccharide mediated mast cells induce IL-10 producing regulatory T cells through the ICOSL/ICOS axis. Clin Immunol 142: 269-279.
43. Ganeshan K, Bryce PJ (2012) Regulatory T cells enhance mast cell production of IL-6 via surface-bound TGF-beta. J Immunol 188: 594-603.